Satellos Bioscience (TSE:MSCL) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Satellos Bioscience Inc. has reached a critical milestone by submitting a proposal to conduct a Phase 1 clinical trial for its new drug SAT-3247, aimed at treating muscle diseases. The trial is set to begin in the third quarter of 2024, signaling the company’s transition to a clinical-stage entity. SAT-3247, an oral small molecule drug, shows promise in regenerating skeletal muscle affected by conditions like Duchenne muscular dystrophy.
For further insights into TSE:MSCL stock, check out TipRanks’ Stock Analysis page.
